Kymos Group continues to expand its European footprint and scientific capabilities with the acquisition of Particle Analytical ApS, the Danish CRO specialized in particle analysis and solid state characterization.
This strategic move reinforces Kymos’ position as a comprehensive one-stop-shop analytical partner for the biopharmaceutical industry, incorporating highly specialized expertise in an area that is increasingly critical in drug development.
From strategic collaboration to full integration
The acquisition is the natural outcome of years of successful collaboration between both companies. What began as a partnership agreement has evolved into a full integration, driven by a shared vision: to build a stronger European group capable of competing with major multinational players in the sector, while maintaining scientific excellence and close client relationships.
As Joan Puig de Dou, CEO of Kymos Group, states:
This is a strategic acquisition for Kymos Group in an area of expertise not fully covered by other companies within the Group. It is fully complementary and strengthens our positioning as a one-stop-shop service provider for the biopharmaceutical industry. It also represents a significant opportunity to consolidate our presence in the Nordic countries.
Expanding capabilities in particle analysis testing and solid state characterization
Founded in 2000 and located at DTU Science Park in Denmark, Particle Analytical has built a strong international reputation in solid state analysis and particle characterization. The company operates under European GMP certification and has successfully passed FDA inspections.
Particle Analytical has become a trusted partner for companies seeking robust regulatory data, highly reproducible results, and scientific support throughout the entire product lifecycle.
As a GMP-certified laboratory, Particle Analytical offers a comprehensive portfolio of analytical and technical services. Its approach is focused on ensuring regulatory compliance, improving compound performance, and accelerating drug development processes.
Its capabilities include:
- Solid state characterization to understand the physical forms of APIs and excipients.
- Particle size and morphology determination, critical factors for solubility, dissolution, and bioavailability.
- Polymorph analysis using advanced techniques such as X-ray diffraction (XRD/XRPD), Raman spectroscopy, and Dynamic Light Scattering (DLS).
- Development and validation of analytical methods under GMP conditions to support clinical trials.
- Comprehensive regulatory support, including the generation of data suitable for submissions to authorities such as FDA and EMA.
- Troubleshooting in manufacturing, batch quality control, and bioequivalence studies.
These capabilities directly complement Kymos’ analytical and bioanalytical service offering, enabling the Group to provide even more comprehensive solutions to its clients.
Strengthening a growing European group
Founded in 2001 in Barcelona, Kymos has become a fast-growing European CRO with laboratories in Spain, Italy, and Germany, and a recently established affiliate in South Korea. Over the past three years, the Group has maintained sustained annual growth of approximately 25%, with around 50% of its activity focused on biologics and advanced therapies.
The integration of Particle Analytical strengthens both our technical expertise and our geographical presence in Northern Europe, reinforcing our ambition to build a leading European analytical platform based on scientific excellence, regulatory rigor, and long-term client partnerships.
